[{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"6e8c9c85-9d26-4c35-8860-c80648e49b52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02188264","created_at":"2021-01-18T10:12:45.005Z","updated_at":"2025-02-25T15:25:18.307Z","phase":"Phase 1","brief_title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02188264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAF1 • MAPK1","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAF1 • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/29/2014","start_date":" 08/29/2014","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2025-02-11"},{"id":"2d8fede0-d3af-4a3f-8d61-856862f007e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03128034","created_at":"2021-01-18T15:24:33.202Z","updated_at":"2025-02-25T16:31:10.471Z","phase":"Phase 1/2","brief_title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","source_id_and_acronym":"NCT03128034","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/24/2017","start_date":" 10/24/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2025-02-07"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"5cbe18a7-53bc-4741-8463-14864cc423d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013423","created_at":"2023-08-28T14:08:26.842Z","updated_at":"2025-02-25T17:32:18.916Z","phase":"Phase 2","brief_title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","source_id_and_acronym":"NCT06013423","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 10/31/2031","primary_completion_date":" 10/31/2031","study_txt":" Completion: 10/31/2032","study_completion_date":" 10/31/2032","last_update_posted":"2025-01-31"},{"id":"86dc7e81-ec59-452b-a3ee-1c37d19391d6","acronym":"NCI-2019-03188","url":"https://clinicaltrials.gov/study/NCT03970096","created_at":"2021-01-18T19:31:38.073Z","updated_at":"2024-07-02T16:35:00.086Z","phase":"Phase 2","brief_title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03970096 - NCI-2019-03188","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-05-30"},{"id":"34e695f6-dbe3-425d-b9ce-de960e381284","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644016","created_at":"2021-01-19T20:39:14.570Z","updated_at":"2024-07-02T16:35:01.196Z","phase":"Phase 2","brief_title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","source_id_and_acronym":"NCT04644016","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-05-24"},{"id":"d7ed8a2f-8937-4cbd-aa4d-ea29935f9c24","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195633","created_at":"2021-01-18T20:26:55.926Z","updated_at":"2024-07-02T16:35:01.612Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","source_id_and_acronym":"NCT04195633","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-23"},{"id":"27578ddc-f283-4d0d-bcd4-108743a5b2fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530487","created_at":"2021-01-18T21:41:28.381Z","updated_at":"2024-07-02T16:35:10.209Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","source_id_and_acronym":"NCT04530487","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 05/09/2025","primary_completion_date":" 05/09/2025","study_txt":" Completion: 05/09/2025","study_completion_date":" 05/09/2025","last_update_posted":"2024-04-11"},{"id":"1a870e3d-d1a5-4225-80df-e89da512381b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03013933","created_at":"2024-02-22T16:25:29.863Z","updated_at":"2024-07-02T16:35:18.227Z","phase":"Phase 1","brief_title":"Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT03013933","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFRSF8 • CD68","pipe":"","alterations":" ","tags":["TNFRSF8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 05/03/2017","start_date":" 05/03/2017","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 05/24/2022","study_completion_date":" 05/24/2022","last_update_posted":"2024-02-22"},{"id":"a660173e-535e-4057-9814-041d32dd6698","acronym":"","url":"https://clinicaltrials.gov/study/NCT00719888","created_at":"2021-01-18T02:42:00.338Z","updated_at":"2024-07-02T16:35:24.418Z","phase":"Phase 2","brief_title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","source_id_and_acronym":"NCT00719888","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 11/18/2005","start_date":" 11/18/2005","primary_txt":" Primary completion: 12/22/2023","primary_completion_date":" 12/22/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2024-01-05"},{"id":"20bb3a60-35cb-4903-9d63-a1cf0ddca8cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01962636","created_at":"2021-01-18T08:55:07.216Z","updated_at":"2024-07-02T16:35:30.509Z","phase":"","brief_title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","source_id_and_acronym":"NCT01962636","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-03"},{"id":"9ee14615-2219-4b64-beee-b0a3fb7501ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT00571662","created_at":"2021-02-17T12:52:43.145Z","updated_at":"2024-07-02T16:35:31.868Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant","source_id_and_acronym":"NCT00571662","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/08/2000","start_date":" 12/08/2000","primary_txt":" Primary completion: 12/30/2008","primary_completion_date":" 12/30/2008","study_txt":" Completion: 12/30/2008","study_completion_date":" 12/30/2008","last_update_posted":"2023-10-24"},{"id":"0d3ee8f5-d80e-4d1b-9490-6b52ff00aad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816413","created_at":"2021-07-05T16:06:13.151Z","updated_at":"2024-07-02T16:35:40.198Z","phase":"Phase 1/2","brief_title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","source_id_and_acronym":"NCT00816413","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q) • Chr del(7q)","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • cyclosporine • ondansetron intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-08-14"},{"id":"51dc3555-e944-4b77-91ac-39cecd6429cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00896493","created_at":"2021-01-18T03:26:13.987Z","updated_at":"2024-07-02T16:35:48.244Z","phase":"Phase 2","brief_title":"Ph II of Non-myeloablative Allogeneic Transplantation Using TLI \u0026 ATG In Patients w/ Cutaneous T Cell Lymphoma","source_id_and_acronym":"NCT00896493","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 11/06/2021","primary_completion_date":" 11/06/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-05-11"},{"id":"6b48bb98-5d08-4277-87fc-9cbfba13b91d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00796068","created_at":"2021-01-18T03:01:17.895Z","updated_at":"2025-02-25T12:35:31.293Z","phase":"Phase 2","brief_title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","source_id_and_acronym":"NCT00796068","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD34 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 130","initiation":"Initiation: 02/24/2009","start_date":" 02/24/2009","primary_txt":" Primary completion: 12/14/2021","primary_completion_date":" 12/14/2021","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2023-02-17"},{"id":"f8abd97f-376f-47a2-ae4b-380dbf3c9def","acronym":"","url":"https://clinicaltrials.gov/study/NCT01811368","created_at":"2021-01-18T08:02:05.716Z","updated_at":"2024-07-02T16:35:59.858Z","phase":"Phase 2","brief_title":"Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01811368","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • cyclosporin A microemulsion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/12/2013","start_date":" 03/12/2013","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-11-30"},{"id":"e5847a40-5b30-420c-89e4-cd5a71acd410","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756572","created_at":"2022-01-21T22:01:58.163Z","updated_at":"2024-07-02T16:36:20.983Z","phase":"Phase 2","brief_title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT02756572","lead_sponsor":"University of Washington","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sirolimus • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2016","start_date":" 09/22/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2021-11-08"},{"id":"38d14d6d-5071-42a3-8a27-dc0461c5c8bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00412360","created_at":"2021-01-18T01:26:52.451Z","updated_at":"2024-07-02T16:36:22.252Z","phase":"Phase 3","brief_title":"Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)","source_id_and_acronym":"NCT00412360","lead_sponsor":"Medical College of Wisconsin","biomarkers":" FLT3 • HLA-DRB1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 224","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2021-10-28"},{"id":"a169c1d6-01ea-49b4-a29f-664779e841f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00051311","created_at":"2021-09-09T20:53:12.416Z","updated_at":"2024-07-02T16:36:24.667Z","phase":"Phase 2","brief_title":"Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers","source_id_and_acronym":"NCT00051311","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD4 • HLA-B","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD4 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 01/03/2003","start_date":" 01/03/2003","primary_txt":" Primary completion: 09/25/2014","primary_completion_date":" 09/25/2014","study_txt":" Completion: 09/25/2014","study_completion_date":" 09/25/2014","last_update_posted":"2021-09-09"},{"id":"d1582dd1-e768-4f7e-b5d2-a0089b8a5d93","acronym":"","url":"https://clinicaltrials.gov/study/NCT00919503","created_at":"2021-01-18T03:33:26.727Z","updated_at":"2024-07-02T16:36:26.391Z","phase":"Phase 2","brief_title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","source_id_and_acronym":"NCT00919503","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 07/31/2009","start_date":" 07/31/2009","primary_txt":" Primary completion: 06/10/2020","primary_completion_date":" 06/10/2020","study_txt":" Completion: 06/10/2020","study_completion_date":" 06/10/2020","last_update_posted":"2021-08-13"},{"id":"68f83ef2-b454-4e39-b176-4027e828c89d","acronym":"NCI-2018-01302","url":"https://clinicaltrials.gov/study/NCT03602898","created_at":"2021-01-18T17:42:45.778Z","updated_at":"2024-07-02T16:36:28.451Z","phase":"Phase 2","brief_title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT03602898 - NCI-2018-01302","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" FLT3 • KMT2A • HLA-DRB1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • methotrexate • fludarabine IV • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 09/17/2023","primary_completion_date":" 09/17/2023","study_txt":" Completion: 09/17/2023","study_completion_date":" 09/17/2023","last_update_posted":"2021-06-30"},{"id":"af6ac81b-6eb0-4bca-8c77-37df633e7f99","acronym":"","url":"https://clinicaltrials.gov/study/NCT02424968","created_at":"2021-01-18T11:35:59.667Z","updated_at":"2024-07-02T16:36:28.680Z","phase":"Phase 2","brief_title":"CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma","source_id_and_acronym":"NCT02424968","lead_sponsor":"Robert Lowsky","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 07/03/2020","primary_completion_date":" 07/03/2020","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2021-06-24"},{"id":"81494b2c-8a21-47c9-8b59-314c04d5665d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00378534","created_at":"2021-01-18T01:18:56.890Z","updated_at":"2024-07-02T16:36:29.023Z","phase":"Phase 2","brief_title":"Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants","source_id_and_acronym":"NCT00378534","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 09/01/2006","start_date":" 09/01/2006","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2021-06-16"}]